Tenax Therapeutics (TENX) Operating Expenses (2010 - 2026)
Tenax Therapeutics recorded quarterly Operating Expenses of $16.6 million in Q1 2026, up 0.75% quarter-over-quarter from $16.4 million in Q4 2025, and up 46.17% year-over-year from $11.3 million in Q1 2025.
Tenax Therapeutics' Operating Expenses history runs 16 years deep, the most recent figure standing at $16.6 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 46.17% year-over-year to $16.6 million; the TTM figure through Mar 2026 stood at $61.6 million (up 128.87% YoY), while the FY2025 annual figure was $56.4 million, up 189.24% from the prior year.
- Operating Expenses came in at $16.6 million for Q1 2026 at Tenax Therapeutics, up from $16.4 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $16.8 million in Q3 2025 to a low of $1.2 million in Q2 2023.
- A 5-year average of $6.6 million and a median of $3.7 million in 2024 frame the typical range for Operating Expenses.
- Across the five-year window, Operating Expenses slumped 88.55% in 2022 and jumped 263.84% in 2025, its largest moves.
- Tenax Therapeutics' Operating Expenses stood at $2.6 million in 2022, then soared by 30.78% to $3.3 million in 2023, then surged by 118.35% to $7.3 million in 2024, then jumped by 125.48% to $16.4 million in 2025, then climbed by 0.75% to $16.6 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $16.6 million, $16.4 million, and $16.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.33 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -138.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.85 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 898.54 Mn |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - | 16.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.57 Mn |
| Dec 31, 2025 | 16.45 Mn |
| Sep 30, 2025 | 16.81 Mn |
| Jun 30, 2025 | 11.79 Mn |
| Mar 31, 2025 | 11.34 Mn |
| Dec 31, 2024 | 7.30 Mn |
| Sep 30, 2024 | 4.62 Mn |
| Jun 30, 2024 | 3.67 Mn |
| Mar 31, 2024 | 3.91 Mn |
| Dec 31, 2023 | 3.34 Mn |
| Sep 30, 2023 | 2.12 Mn |
| Jun 30, 2023 | 1.24 Mn |
| Mar 31, 2023 | 1.54 Mn |
| Dec 31, 2022 | 2.55 Mn |
| Sep 30, 2022 | 2.92 Mn |
| Jun 30, 2022 | 2.86 Mn |
| Mar 31, 2022 | 2.72 Mn |
| Dec 31, 2021 | 3.21 Mn |
| Sep 30, 2021 | 3.80 Mn |
| Jun 30, 2021 | 1.96 Mn |
| Mar 31, 2021 | 23.75 Mn |
| Dec 31, 2020 | 2.83 Mn |
| Sep 30, 2020 | 2.23 Mn |
| Jun 30, 2020 | 2.14 Mn |
| Mar 31, 2020 | -2.67 Mn |
| Dec 31, 2019 | 14.30 Mn |
| Sep 30, 2019 | -2.26 Mn |
| Jun 30, 2019 | -1.82 Mn |
| Mar 31, 2019 | -1.66 Mn |
| Dec 31, 2018 | 11.56 Mn |
| Sep 30, 2018 | -1.55 Mn |
| Jun 30, 2018 | -1.89 Mn |
| Mar 31, 2018 | -1.22 Mn |
| Dec 31, 2017 | 17.03 Mn |
| Sep 30, 2017 | -1.31 Mn |
| Jun 30, 2017 | -3.01 Mn |
| Mar 31, 2017 | -3.50 Mn |
| Dec 31, 2016 | 67.53 Mn |
| Sep 30, 2016 | -4.50 Mn |
| Jun 30, 2016 | -4.67 Mn |
| Mar 31, 2016 | 5.71 Mn |
| Dec 31, 2015 | 10.43 Mn |
| Sep 30, 2015 | 3.10 Mn |
| Jun 30, 2015 | 4.92 Mn |
| Apr 30, 2013 | 1.42 Mn |
| Jan 31, 2013 | 1.81 Mn |
| Oct 31, 2012 | 1.20 Mn |
| Jul 31, 2012 | 1.95 Mn |
| Apr 30, 2012 | 1.96 Mn |
| Jan 31, 2012 | 2.02 Mn |
| Oct 31, 2011 | 2.15 Mn |
| Jul 31, 2011 | 2.45 Mn |
| Apr 30, 2011 | 2.77 Mn |
| Jan 31, 2011 | 2.78 Mn |
| Oct 31, 2010 | 2.08 Mn |
| Jul 31, 2010 | 3.03 Mn |